Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. NUTX
stocks logo

NUTX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
249.77M
-3.05%
4.685
-57.87%
243.30M
+14.88%
2.540
-0.78%
245.08M
+0.45%
2.463
-183.5%
Estimates Revision
The market is revising Upward the revenue expectations for Nutex Health Inc. (NUTX) for FY2025, with the revenue forecasts being adjusted by 12.22% over the past three months. During the same period, the stock price has changed by 88.04%.
Revenue Estimates for FY2025
Revise Upward
up Image
+12.22%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+141.32%
In Past 3 Month
Stock Price
Go Up
up Image
+88.04%
In Past 3 Month
Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 252.50 USD with a low forecast of 205.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 252.50 USD with a low forecast of 205.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 156.790
sliders
Low
205.00
Averages
252.50
High
300.00
Current: 156.790
sliders
Low
205.00
Averages
252.50
High
300.00
Maxim
Maxim
Buy
downgrade
$225 -> $205
2025-08-26
Reason
Maxim
Maxim
Price Target
$225 -> $205
2025-08-26
downgrade
Buy
Reason
Maxim lowered the firm's price target on Nutex Health to $205 from $225 and keeps a Buy rating on the shares. On August 14th, the company filed an NT 10-Q notification of inability to timely file its 10-Q for the three months ended 6/30/25, due to the incorrect accounting classification of certain non-cash obligations, the analyst tells investors in a research note. The firm views the accounting restatements, arbitration dynamics, and lawsuits against Nutex's primary arbitration vendor, HaloMD, as potential headwinds to the stock price, Maxim added.
Maxim
Maxim
Buy
maintain
$100 -> $225
2025-05-20
Reason
Maxim
Maxim
Price Target
$100 -> $225
2025-05-20
maintain
Buy
Reason
Benchmark
Buy
upgrade
$150 -> $300
2025-05-15
Reason
Benchmark
Price Target
$150 -> $300
2025-05-15
upgrade
Buy
Reason
Maxim Group
Anthony Vendetti
Strong Buy
Maintains
$75 → $100
2025-04-08
Reason
Maxim Group
Anthony Vendetti
Price Target
$75 → $100
2025-04-08
Maintains
Strong Buy
Reason
Maxim raised the firm's price target on Nutex Health to $100 from $75 and keeps a Buy rating on the shares. The company delivered significantly better-than-expected Q4 results, driven largely by the company's success in achieving improved reimbursement by advancing claims through the No Surprises Act's IDR - independent dispute resolution - process, the analyst tells investors in a research note. Beyond IDR activity, Nutex continues to advance its core growth strategy, with its hospitals expanding service lines to treat higher-acuity patients and to drive increased inpatient and observation visit volumes, the firm adds.
Maxim Group
Anthony Vendetti
Strong Buy
Maintains
$50 → $75
2025-02-13
Reason
Maxim Group
Anthony Vendetti
Price Target
$50 → $75
2025-02-13
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Nutex Health Inc (NUTX.O) is 8.96, compared to its 5-year average forward P/E of -24.06. For a more detailed relative valuation and DCF analysis to assess Nutex Health Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-24.06
Current PE
8.96
Overvalued PE
73.04
Undervalued PE
-121.17

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
61.40
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
171.05
Undervalued EV/EBITDA
-48.25

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
3.10
Current PS
0.00
Overvalued PS
10.37
Undervalued PS
-4.16
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

NUTX News & Events

Events Timeline

(ET)
2025-12-04
05:40:00
Nutex Health Extends Stock Repurchase Program to March 2026
select
2025-11-26 (ET)
2025-11-26
16:12:33
Nutex Health claims 'Capybara Research appears to be a non-existent entity'
select
2025-11-25 (ET)
2025-11-25
10:43:49
Capybara Research Accuses Nutex Health of Fraudulent Business Practices
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.0
12-04Newsfilter
Nutex Health Extends $25 Million Stock Repurchase Program to March 2026
  • Repurchase Program Extension: Nutex Health's Board of Directors has approved an extension of the previously authorized $25 million stock repurchase program until March 31, 2026, aimed at enhancing shareholder value and offsetting dilution from new hospital constructions.
  • Market-Responsive Implementation: The repurchase plan will be executed flexibly based on market conditions and the company's financial health, ensuring shares are bought back at optimal prices to bolster market confidence.
  • Strategic Confidence Demonstration: This extension reflects the Board's confidence in Nutex's long-term strategy, indicating the company's commitment to enhancing shareholder returns through effective capital management.
  • Compliance Assurance: The repurchase program will adhere to Rule 10b-18 and a Rule 10b5-1 trading plan under the Securities Exchange Act of 1934, ensuring compliance and minimizing legal risks.
[object Object]
Preview
8.0
12-04PRnewswire
Nutex Health Extends $25 Million Stock Repurchase Program to March 2026
  • Repurchase Program Extension: Nutex Health's Board of Directors has approved an extension of the previously authorized $25 million stock repurchase program through March 31, 2026, aimed at enhancing shareholder value by mitigating dilution from stock compensation obligations.
  • Market Response Consideration: The repurchase plan will be implemented in accordance with Rule 10b-18 under the Securities Exchange Act of 1934, which is expected to bolster market confidence in the company's long-term strategy, although the timing and number of shares repurchased will be influenced by market conditions.
  • Financial Health Assurance: The execution of the repurchase program will help offset dilution from stock compensation obligations related to the construction and ramping of hospitals, ensuring the company remains competitive in the rapidly growing healthcare market.
  • Strategic Confidence Demonstration: This extension of the repurchase program underscores the Board's confidence in Nutex Health's long-term growth strategy, aiming to attract investor interest through ongoing shareholder returns.
[object Object]
Preview
8.0
12-04NASDAQ.COM
Nutex Health Expands $25 Million Share Buyback Initiative Until March 2026

  • Share Repurchase Program Extended: Nutex Health Inc. has extended its $25 million share repurchase program through March 31, 2026, with repurchases starting around December 4.

  • Purpose of the Program: The program aims to enhance shareholder value and mitigate dilution from stock compensation related to ongoing hospital construction and ramp-up.

  • Original Announcement: The buyback plan was initially announced on August 14, intended for a six-month period following the filing of the company's June-quarter Form 10-Q.

  • Market Reaction: In pre-market trading, Nutex Health shares rose by 2.31%, reaching $134.80 on the Nasdaq.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Nutex Health Inc (NUTX) stock price today?

The current price of NUTX is 156.79 USD — it has increased 19.01 % in the last trading day.

arrow icon

What is Nutex Health Inc (NUTX)'s business?

Nutex Health Inc. is a healthcare management and operations company. The Company operates in three segments: the Hospital division, the Population Health Management (PHM) division, and the Real Estate division. The Hospital division owns, develops and operates healthcare models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. In addition, it has financial and operating relationships with multiple professional entities and real estate entities. The Population Health Management division owns and operates provider networks, such as Independent Physician Associations (IPAs). Through its Management Services Organization (MSO), it provides management, administrative and other support services to its affiliated hospitals and physician groups. The Real Estate division comprises the Real Estate Entities, which owns the land and hospital buildings which are leased to its hospital entities.

arrow icon

What is the price predicton of NUTX Stock?

Wall Street analysts forecast NUTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NUTX is 252.50 USD with a low forecast of 205.00 USD and a high forecast of 300.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Nutex Health Inc (NUTX)'s revenue for the last quarter?

Nutex Health Inc revenue for the last quarter amounts to 267.80M USD, increased 239.87 % YoY.

arrow icon

What is Nutex Health Inc (NUTX)'s earnings per share (EPS) for the last quarter?

Nutex Health Inc. EPS for the last quarter amounts to 7.76 USD, decreased -551.16 % YoY.

arrow icon

What changes have occurred in the market's expectations for Nutex Health Inc (NUTX)'s fundamentals?

The market is revising Upward the revenue expectations for Nutex Health Inc. (NUTX) for FY2025, with the revenue forecasts being adjusted by 12.22% over the past three months. During the same period, the stock price has changed by 88.04%.
arrow icon

How many employees does Nutex Health Inc (NUTX). have?

Nutex Health Inc (NUTX) has 800 emplpoyees as of December 05 2025.

arrow icon

What is Nutex Health Inc (NUTX) market cap?

Today NUTX has the market capitalization of 1.11B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free